The global breast cancer diagnostics market is experiencing significant growth due to the rising incidence of breast cancer, increasing awareness about early detection, and advancements in diagnostic technologies. The demand for mammography, ultrasound, MRI, and molecular diagnostic tests is expanding as healthcare providers focus on early and accurate diagnosis to improve patient outcomes. The integration of artificial intelligence (AI) in imaging systems and liquid biopsy techniques is enhancing diagnostic accuracy and efficiency. Government initiatives, screening programs, and research funding are further driving market expansion.
Data Bridge Market Research analyzes that the Global Breast Cancer Diagnostics Market is expected to reach the value of USD 8.65 billion by 2030, at a CAGR of 9.2% during the forecast period.
To know more, visit https://www.databridgemarketresearch.com/reports/global-breast-cancer-diagnostics-market
Below are the Top Breast Cancer Diagnostics Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Hologic, Inc.
|
Hologic, Inc. is a leading global medical technology company specializing in women's health solutions, including breast cancer diagnostics. The company is known for its advanced mammography systems, such as 3D Tomosynthesis (Genius™ 3D Mammography), which enhances early breast cancer detection.
|
|
Americas, Middle East and Africa, Asia-Pacific, and Europe
|
In December 2022, Hologic, Inc. announced new study data showing that the Breast Cancer Index test identified for patients with early-stage, hormone-receptor-positive (HR+) breast cancer is benefiting from the addition of ovarian function suppression (OFS) to primary adjuvant endocrine therapy. The Breast Cancer Index test is the first biomarker to be evaluated in a cohort from the landmark Suppression of Ovarian Function Trial (SOFT).
|
|
2.
|
Siemens Healthcare GmbH
|
Siemens Healthcare GmbH (Siemens Healthineers) is a subsidiary of Siemens AG, offering cutting-edge imaging and diagnostic solutions for breast cancer detection. The company’s MAMMOMAT Revelation and MAMMOMAT Inspiration mammography systems provide high-quality imaging with lower radiation doses.
|
|
Americas, Middle East and Africa, Asia-Pacific, and Europe
|
In November 2022, Siemens Healthineers Gmbh and Atrium Health, a leading healthcare provider known for cancer and cardiac care programs, has announced a multi-year value partnership. This strategic agreement focuses on improving access to care in Atrium Health's service area in the United States, improving health equity and increasing economic mobility.
|
|
3.
|
F. Hoffmann-La Roche Ltd.
|
Roche is a Swiss multinational healthcare company with a strong presence in breast cancer diagnostics through its immunohistochemistry (IHC) and molecular diagnostic tests. Roche’s VENTANA and cobas platforms play a crucial role in early breast cancer detection and treatment planning.
|
|
Americas, Middle East and Africa, Asia-Pacific, and Europe
|
In October 2022, F. Hoffmann-La Roche Ltd announced US Food and Drug Administration (FDA) approved the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify metastatic breast cancer patients with low HER2 expression ENHERTU is a specifically engineered HER2-directed antibody drug conjugate (ADC) developed and commercialized by AstraZeneca and Daiichi Sankyo.
|
|
4.
|
Koninklijke Philips N.V.
|
Philips is a Dutch multinational corporation specializing in healthcare technology, including breast cancer diagnostics. The company provides advanced mammography and ultrasound solutions, such as MicroDose SI and Affiniti ultrasound systems, which offer high-resolution imaging with reduced radiation exposure.
|
|
Americas, Middle East and Africa, Asia-Pacific, and Europe
|
In November 2022, Koninklijke Philips N.V. announced the global launch of a next-generation compact portable ultrasound solution at the Radiological Society of North America (RSNA) annual meeting to bring the diagnostic quality associated with premium cart-based ultrasound systems to more patients.
|
|
5.
|
Abbott
|
Abbott is a global healthcare company that develops innovative diagnostic solutions, including breast cancer detection tools. The company’s molecular and immunoassay-based tests help identify breast cancer biomarkers, aiding in early diagnosis and treatment decisions. Abbott focuses on delivering high-precision, rapid diagnostics to improve breast cancer patient care.
|
|
America, Middle East and Africa, Asia-Pacific, and Europe
|
|
Conclusion
The global breast cancer diagnostics market is poised for continued expansion as technological advancements improve the accuracy and accessibility of diagnostic solutions. Increased investments in AI-powered imaging, molecular diagnostics, and non-invasive screening methods are revolutionizing early detection efforts. While cost and accessibility challenges persist, growing awareness, government support, and ongoing research will sustain market growth and enhance patient outcomes in the coming years.
